Compare Quest Diagnostics Inc (DGX) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KeyCorp — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while KeyCorp trades at $20.14 (market cap $21.16B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and KeyCorp pays the higher dividend (4.14%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and KeyCorp for 66 Days on average.
| DGX | KEY | |
|---|---|---|
Market Cap | $25.06B | $21.16B |
Volume | 927,361 | 16,207,672 |
Sector | Health | Financials |
52-Week High | $247.45 | $23.99 |
52-Week Low | $173.49 | $16.78 |
Typical Hold Time | 56 Days | 66 Days |
Enterprise Value | $30.82B | $34.34B |
Dividend Yield | 1.52% | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
KeyCorp (KEY) trades at $19.83, down 1.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank has beaten EPS estimates for three consecutive quarters, with a Q3 2026 estimate of $0.4615. Revenue rebounded to $7.29B in 2025, and the net income margin improved to 26.72%. Recent corporate actions include a $0.21 dividend and key executive appointments in wealth and retail banking.
The outlook is cautiously optimistic, supported by strong analyst consensus (60.79% buy rating) and a $25.00 price target implying 26% upside. Investment opportunities include earnings momentum and shareholder returns via dividends and buybacks. Risks involve interest rate sensitivity, competitive pressures on margins, and macroeconomic uncertainty affecting loan growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
